Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.79 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344464 | 0.86 | PIK3CA (0.63) | PIK3CAMAPTBRAF | |
| SCHEMBL23326380 | 0.84 | PIK3CA (0.55) | PIK3CAGRIK1MEN1KMT2AMAPT | |
| SCHEMBL23344505 | 0.82 | PIK3CA (0.86) | PIK3CAMEN1KMT2AMAPTHTT | |
| SCHEMBL23344439 | 0.82 | PIK3CA (0.76) | PIK3CAMEN1KMT2AMAPTHTT | |
| SCHEMBL23344503 | 0.81 | GSK3A (0.56) | GRIK1MEN1KMT2AMAPTHTT | |
| SCHEMBL23344479 | 0.79 | PIK3CA (0.71) | PIK3CAMEN1KMT2AMAPTHTT | |
| SCHEMBL20595312 | 0.79 | AURKA (0.52) | PIK3CAGRIK1MEN1KMT2AMAPT | |
| SCHEMBL23344490 | 0.79 | PIK3CA (0.65) | PIK3CAMEN1KMT2A | |
| SCHEMBL20595368 | 0.79 | MEN1 (0.50) | PIK3CAGRIK1MEN1KMT2AMAPT | |
| SCHEMBL20595313 | 0.78 | CDK8 (0.52) | PIK3CAGRIK1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117894-B2 | Pyridopyrazine compounds and uses thereof | CITY OF HOPE (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210139476-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117894-B2 | Pyridopyrazine compounds and uses thereof | PDXK, DPYD, PNPO | PIK3CA 1262/4885GRIK1 1709/4885MEN1 4106/4885 |
| US-20210139476-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | PDXK, DPYD, PNPO | PIK3CA 1262/4885GRIK1 1709/4885MEN1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.